View Single Post
Old 11-08-2013, 02:10 AM
jnewk jnewk is offline
Junior Member
 
Join Date: Oct 2006
Location: Las Vegas, NV
Posts: 94
15 yr Member
jnewk jnewk is offline
Junior Member
 
Join Date: Oct 2006
Location: Las Vegas, NV
Posts: 94
15 yr Member
Default

Quote:
Originally Posted by Lynn View Post
This article I have found states that the survival rate with MS related PML is up around the 70% mark - BUT consequential disability is usually high. IRIS or immune reconstitution inflammatory syndrome occurs, in almost all patients after they are treated with plasma exchange to rapidly remove all traces of the drug.

IRIS results (as the name suggests) in brain inflammation - my doc kind of explained it like having very serious back-to-back or concurrent relapses.

Janet, read this article - one thing that did strike me when I was reading your earlier post was that you mentioned other health problems, and I wondered about past drug interactions - if you are JC+ and have used certain other drugs (methotextrate to name one - but I know there are more - especially cancer drugs) - then for sure your risk for PML with Tysabri increases massively I don't know about Tec, but worth checking.

http://www.medpagetoday.com/Neurolog...eurology/26628

Regards
Thank you Lynn...I will read the article in the morning. yes, I've had a lot of serious health issues and take a bucket full of meds daily and have had problems with contradictions before. I just did not have a good feeling about this and maybe its my over thinking but ultimately, I still see the risks far outweighing the possible benefits. And honestly as well, the idea of takng something with even nonfatal but severe side effects doesn't feel right either. I'm already sick, I don't need to take something that will make me feel sicker so that it might make my MS slow down? Not much of a trade off. Its good to be able to "talk it out" with you all on this board. it really does help.

janet
jnewk is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
SallyC (11-08-2013)